Vyvgart Hytrulo CIDP denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vyvgart hytrulo cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for Vyvgart Hytrulo in CIDP

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc, subcutaneous formulation) is a high-cost specialty biologic, and Blue Cross Blue Shield plans universally require prior authorization (PA) before approving it for CIDP treatment. A PA-required denial simply means the authorization was either not obtained before prescribing, was submitted with insufficient documentation, or was reviewed and denied on substantive grounds. Each scenario has a distinct remedy.

## Why This Is Appealable (or Preventable)

If the PA was denied on substantive grounds (rather than missed procedurally), you have full appeal rights under ACA §2719 and ERISA §503. If it was denied for lack of documentation, a peer-to-peer review between the prescribing neurologist and the BCBS medical director is often the fastest path to approval — request one immediately after any denial.

## Federal Appeal Framework

• Peer-to-peer review: Request this within 24-72 hours of denial. The neurologist speaks directly with the plan's reviewing physician, which resolves documentation gaps faster than formal appeals in many cases.
• Internal appeal: Submit under ACA §2719 / ERISA §503 with complete clinical documentation. The plan must decide within regulatory timeframes (typically 30 days for pre-service appeals).
• External review: If the internal appeal is denied, you have the right to independent external review. Preserve this right by filing within the window on the denial letter (commonly around four months).
• Expedited review: Available when the standard timeline would seriously jeopardize the patient's health or functional status.

## Documentation to Gather

1. CIDP diagnosis confirmation — neurology records, nerve conduction studies, and clinical findings establishing the diagnosis consistent with applicable guideline criteria. 2. Prior treatment history — a chronological list of all treatments tried for CIDP, with start/end dates, agents used, and documented outcomes (insufficient response, intolerance, or clinical reason for discontinuation). 3. Current disease severity — objective functional assessments from the neurologist's chart demonstrating the clinical burden of the patient's condition. 4. Prescriber medical-necessity letter — explaining why Vyvgart Hytrulo is medically necessary for this patient and how the patient meets the criteria in both the FDA prescribing label and the BCBS prior-authorization criteria. 5. BCBS PA criteria — download the current published PA criteria for this drug from BCBS and confirm each criterion is addressed explicitly in your submission.

## Criteria-Mapping Structure

Obtain the BCBS prior-authorization criteria document and the FDA-approved prescribing information. List each PA requirement alongside the chart evidence that satisfies it. If the PA was denied for failure to meet a specific criterion, focus the appeal on that criterion with direct chart citations. Never state specific eligibility thresholds from memory — pull them from the current BCBS PA criteria and the FDA label, as these are updated periodically.